ºñ¼Ò¼¼Æ÷¼º Æó¾ÏÀÇ ¹æ»ç¼±Ä¡·á ¼ºÀû
Treatment of Unresectable Non-Small-Cell Lung Cancer with Curative Radiotherapy
´ëÇÑÄ¡·á¹æ»ç¼±°úÇÐȸÁö 1984³â 2±Ç 2È£ p.203 ~ p.211
±èÀÏÇÑ(Kim Il-Han) - ¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±°úÇб³½Ç
ÇϼºÈ¯(Ha Sung-Whan) - ¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±°úÇб³½Ç
¹ÚÂùÀÏ(Park Charn-Il) - ¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±°úÇб³½Ç
½É¿µ¼ö(Shim Young-Soo) - ¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è³ë°æ(Kim Noe-Kyeong) - ¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è±Ù¿(Kim Keun-Youl) - ¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÇÑ¿ëö(Han Yong-Chul) - ¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
From 1979 to 1982, 80 patients with unresectable non-small-cell lung cancer without metastasis were treated with high-dose radiotherapy to the primary and to regional lymph nodes with or without supraclavicular lymphatic in the Department of Therapeutic radiology, Seoul National University Hospital.
Of these, 56 patients (70%) were completely evaluable, and 59 patients (74%) had squamous cell carcinoma, 13% large cell undifferentiated carcinoma and 8% Aden carcinoma. 21 patients (26%) had Stage ¥± and 59 patients (74%) had Stage ¥².
The complete and partial response rate in the high-dose (~ 6,000rad) radiotherapy was 70% with 19% complete response. 69 patients (86%) failed in the treatment, by the failure pattern, 64% had local failure alone, 35% had local failure and distant metastasis and 1% had distant metastasis alone. The failure rate in the thorax was 76% in squamous cell carcinoma, 40% in Aden carcinoma and 20% in large cell undifferentiated carcinoma. Preliminary result shows that actuarial survival at 1, 2 and 3 years were 56%, 26% and 20% in overall patients and 64%, 37% and 21% in Stage ¥± and 54%, 21% and 18% in Stage ¥², respectively. Overall median survival was 14 months; 17 months in Stage ¥± and 13 months in Stage ¥². 8 patients (10%) have lived a minimum of 2 years with no evidence of disease.
There was no fatal complication confirmed to be induced by radiotherapy, so definitive high-dose radiotherapy was tolerated well without major problems and resulted in good local control and survival.
Å°¿öµå
KMID :
0362919840020020203
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Actuarial survival at 1, 2 and 3 years were 56%, 26% and 20% and 64%, 37% and 21% in Stage ¥± and 54%, 21% and 18% in Stage ¥², respectively. Overall median survival was 14 months; 17 months in Stage ¥± and 13 months in Stage ¥².